Ganz P A, Ma P Y, Wang H J, Elashoff R M
J Clin Oncol. 1987 Mar;5(3):472-9. doi: 10.1200/JCO.1987.5.3.472.
A number of biochemical markers have been proposed for monitoring the therapy of small-cell lung cancer (SCLC). This report reviews the experience at a single institution using three biochemical markers, alpha-1-acid glycoprotein (AGP), carcinoembryonic antigen (CEA), and lactate dehydrogenase (LDH), for serially monitoring the therapy of patients with SCLC. AGP measurements identified limited-disease patients more frequently than LDH or CEA, and a combination of markers (AGP and LDH) improves the accuracy of correctly classifying patients with active disease. Each of the markers correctly tracked the clinical response to therapy in approximately two thirds of the subjects. The use of a combination of markers should be considered for monitoring the therapy of SCLC in future clinical trials.
已有多种生化标志物被提出用于监测小细胞肺癌（SCLC）的治疗。本报告回顾了一家机构使用三种生化标志物——α-1-酸性糖蛋白（AGP）、癌胚抗原（CEA）和乳酸脱氢酶（LDH）对SCLC患者治疗进行连续监测的经验。与LDH或CEA相比，AGP检测更频繁地识别出疾病局限期患者，并且标志物组合（AGP和LDH）提高了正确分类活动性疾病患者的准确性。每种标志物在大约三分之二的受试者中正确跟踪了对治疗的临床反应。在未来的临床试验中，应考虑使用标志物组合来监测SCLC的治疗。
